cvkdCadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
#cvkd
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.30 USD
−8.36 M USD
0.00 USD
1.09 M
About Cadrenal Therapeutics, Inc.
Sector
Industry
CEO
Quang X. Pham
Website
Headquarters
Ponte Vedra Beach
Founded
2022
FIGI
BBG019STRT20
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CVKD is 14.77 USD — it has decreased by −11.81% in the past 24 hours. Watch Cadrenal Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cadrenal Therapeutics, Inc. stocks are traded under the ticker CVKD.
CVKD stock has risen by 29.17% compared to the previous week, the month change is a 1.49% rise, over the last year Cadrenal Therapeutics, Inc. has showed a 85.44% increase.
We've gathered analysts' opinions on Cadrenal Therapeutics, Inc. future price: according to them, CVKD price has a max estimate of 45.00 USD and a min estimate of 30.00 USD. Watch CVKD chart and read a more detailed Cadrenal Therapeutics, Inc. stock forecast: see what analysts think of Cadrenal Therapeutics, Inc. and suggest that you do with its stocks.
CVKD reached its all-time high on Jan 20, 2023 with the price of 101.25 USD, and its all-time low was 5.40 USD and was reached on Apr 10, 2024. View more price dynamics on CVKD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CVKD stock is 7.26% volatile and has beta coefficient of 1.82. Track Cadrenal Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cadrenal Therapeutics, Inc. there?
Today Cadrenal Therapeutics, Inc. has the market capitalization of 23.65 M, it has decreased by −8.76% over the last week.
Yes, you can track Cadrenal Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cadrenal Therapeutics, Inc. is going to release the next earnings report on Mar 17, 2025. Keep track of upcoming events with our Earnings Calendar.
CVKD earnings for the last quarter are −2.18 USD per share, whereas the estimation was −1.93 USD resulting in a −13.15% surprise. The estimated earnings for the next quarter are −2.02 USD per share. See more details about Cadrenal Therapeutics, Inc. earnings.
Cadrenal Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CVKD net income for the last quarter is −2.41 M USD, while the quarter before that showed −2.39 M USD of net income which accounts for −0.62% change. Track more Cadrenal Therapeutics, Inc. financial stats to get the full picture.
No, CVKD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 4.00 employees. See our rating of the largest employees — is Cadrenal Therapeutics, Inc. on this list?
Like other stocks, CVKD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cadrenal Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cadrenal Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cadrenal Therapeutics, Inc. stock shows the buy signal. See more of Cadrenal Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.